Menu
We are excited to be at the 24th Annual Bio-IT World Conference & Expo. Join us at booth #724 and meet our BioPharma and Multimodal R&D experts to learn how we help BioPharma companies address challenges throughout the drug development continuum with data solutions tailored to their needs, bringing more effective drugs to the right patients.
If you are attending, don’t miss our talk on Friday, April 4th from 12.10 to 12.40pm, in the AI for Oncology, Precision Medicine & Health track.
“SOPHiA DDM™ for Multimodal: Advancing Precision Oncology with AI-Driven Analytics”
Paul Bernard, Data Engineer, Multimodal R&D, SOPHiA GENETICS
Join this session to explore how SOPHiA DDM™ for Multimodal is shaping the future of cancer care, one breakthrough at a time:
SOPHiA GENETICS is thrilled to be back at ASCO 2025! Meet our experts at booth #32131 to hear about our biopharma solutions. Learn how we are leveraging our unique AI expertise, to provide an unparalleled offering, unlocking insights from complex data types, driving faster discovery of new stratifying biomarkers, in addition to aiding in the commercialization of precision medicines
SOPHiA GENETICS is thrilled to be back at AACR 2025! Visit us at booth #2856 to learn how we advance data-driven medicine, with our cloud-based SOPHiA DDM™ Platform. Discover how it empowers health data interpretation with advanced analytics modules, simplified reporting, and a global community of healthcare institutions. By harnessing the power of AI and multimodal data-driven analytics, we enable you to advance and streamline global access to precision therapies.
Decentralized pan-cancer tumor profiling: A comprehensive performance evaluation of the MSK-IMPACT® Assay with SOPHiA DDM™
Presented by
Julien Pontis, PhD - Technical Product Manager and Lead Data Scientist, SOPHiA GENETICS
Fuad Mohammad, PhD - Senior Bioinformatican, Bioinformatics Product Development, SOPHiA GENETICS
Sunday, April 27 | 2 PM – 5 PM
Poster Board Number: 24
Real-World Insights into the Accuracy and Precision of the Decentralized MSK-ACCESS powered with SOPHiA DDM Solution
Presented by
Florian Klemm, MD, PhD - Technical Product Management Expert, Genomic Research , SOPHiA GENETICS
Monday, April 28 | 9 AM – 12 PM
Poster Board Number: 16
SOPHiA GENETICS is thrilled to be back at this year’s Healthcare Information and Management Systems Society annual meeting. Stop by booth #3460 to meet our team and to learn how our cloud-based SOPHiA DDM™ Platform is empowering clinical researchers to break data silos and improve knowledge sharing. You can also chat with our experts and dem our SOPHiA DDM™ Platform GEN 2. Stay tuned for more information on our Lunch & Learn presentation.
Lunch & Learn
Wednesday, March 5, 2025
12:30 PM - 1:45 PM PT
Caesars Forum
Forum 121
Optimizing genomic analysis workflows by streamlining system integration
Jitin Asnaani, Chief Product Officer, Rhapsody
Wiley Gellar, Senior Product Manager, SOPHiA GENETICS
Next-generation sequencing (NGS) is becoming more cost-effective, delivering deeper actionable insights and driving advancements in precision medicine. However, its rapid growth and increasing adoption in healthcare present significant challenges. Traditional data management methods often operate in silos, resulting in time-consuming processes, limiting scalability, and delaying access to critical insights. In healthcare, the challenge is twofold: it is paramount that sensitive patient data remains highly secure while also being readily accessible to guide time-sensitive decision-making.
To meet these demands and streamline genomic workflows, SOPHiA GENETICS joined forces with Rhapsody to develop an edge-deployed integration container for rapid deployment and seamless system integration. Unlike traditional solutions, this approach intelligently places a smaller, containerized engine on client premises to ensure rapid movement of large genomic data sets. This architecture ensures robust security while enabling fast data movement of large Next Generation Sequencing files, providing effortless interoperability, and scalable, repeatable implementation with minimal complexity.
Attendees will explore key challenges and opportunities in deploying secure, scalable genomic workflows and improving access to actionable insights while ensuring data integrity and compliance.
SOPHiA GENETICS is thrilled to return for ACMG 2025! Visit us at booth #322 to learn more about our SOPHiA DDM™ and Alamut™ Visual Plus platforms for rare and inherited diseases.
Exhibit Theater
Friday, March 21.
11:20 am – 11:50 am.
Theatre 2
Streamlining genomic complexity with SOPHiA DDM™ and Alamut™ Visual Plus
Elexandra Barboza Arguedas, National Children’s Hospital, CCSS, University of Costa Rica, University of Medical Sciences.
Sevana Yaghoubian, MSc - Senior Director of Product Management, SOPHiA GENETICS.
Discover how our AI-powered platform is transforming germline variant analysis and interpretation, enabling scientists to uncover actionable insights with unmatched accuracy and efficiency. This session showcases the innovative features of the new-generation SOPHiA DDM™ Platform and the latest advancements in Alamut™ Visual Plus, purpose-built to optimize workflows and drive impactful outcomes.
Through the perspective of a medical laboratory scientist, discover SOPHiA DDM™’s capabilities for hereditary cancer and exome applications. Experience how its dedicated features set new standards in the assessment of even the most challenging variants and get an exclusive look at exciting functionalities debuting this year.
Boston, MA – January 07, 2025 — SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today that it was honored by Built In on its 2025 Best Places To Work Awards for the fourth consecutive year. SOPHiA GENETICS was named on the Boston mid-size company and overall best places to work lists. The annual awards program includes companies of all sizes.
“We are proud of our company culture that makes us a standout amongst Boston companies. Our team directly contributes to the transformation of healthcare, and our colleagues in Boston and across our global offices feel connected in knowing their work every day truly matters. We are thrilled to be recognized for our culture by Built In once more,” said Manuela Valente, Chief People Officer, SOPHiA GENETICS.
Built In determines the winners of Best Places to Work based on an algorithm, using company data about compensation and benefits. To reflect the benefits candidates are searching for more frequently on Built In, the program also weighs criteria like remote and flexible work opportunities, programs for DEI and other people-first cultural offerings.
“Being recognized as a Best Place to Work is a testament to these companies' commitment to building a workplace where individuals and innovation thrive," says Built In CEO and Founder, Maria Christopoulos Katris. “At Built In, we understand that great companies are powered by great teams, and this achievement showcases their dedication to fostering a culture of growth, inclusivity, and excellence. Congratulations on this well-deserved honor.”
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to transform patient care by expanding access to data-driven medicine globally. It is the creator of the SOPHiA DDM™ Platform, which analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.com and connect with us on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.
ABOUT BUILT IN
Built In is the “always on” recruiting platform that reaches the tech professionals that other leading recruiting platforms don’t. Designed to help companies hire expert tech talent, Built In continuously drives brand awareness with content. Monthly, millions of the industry’s most in-demand global tech professionals visit our site to stay ahead of tech trends and news, learn skills to accelerate their careers, find the right job opportunities and get hired. Thousands of companies, from fast-growing startups to the largest enterprises rely on Built In. By putting their stories in front of our uniquely engaged audience, we help them hire otherwise hard-to-reach technical and expert talent. www.builtin.com
ABOUT BUILT IN’S BEST PLACES TO WORK
Built In’s annual Best Places to Work program honors companies with the best total rewards packages across the U.S. and in the following tech hubs: Atlanta, Austin, Boston, Chicago, Colorado, Dallas, Houston, Los Angeles, Miami, New York, San Diego, San Francisco, Seattle and Washington DC. Best Places to Work is distinct because its algorithm selects tech companies that build their offerings specifically around what tech professionals value in a workplace. https://employers.builtin.com/best-places-to-work
Media Contact:
Kelly Katapodis
[email protected]
Leading community-based practice to utilize increased set of solid tumor applications
Boston, MA and Rolle, Switzerland, November 21, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today that Tennessee Oncology, one of the United States’ largest community-based cancer care specialists that treats nearly half of Tennessee’s cancer patients across 35 clinics, has expanded its relationship with SOPHiA GENETICS to advance its cancer research.
Tennessee Oncology started using SOPHiA GENETICS in early 2024, when it began to validate the liquid biopsy test MSK-ACCESS® powered with SOPHiA DDM™ alongside the SOPHiA DDM™ Hereditary Cancer Solution. As the practice worked with SOPHiA GENETICS throughout the year, it experienced the benefits of utilizing the SOPHiA DDM™ Platform for its next generation sequencing (NGS) testing and today announced it will begin to validate the SOPHiA DDM™ RNAtarget Technology and the SOPHiA DDM™ for Comprehensive Genomic Profiling (CGP) application.
“In our time using SOPHiA DDM™, we have been impressed with the outstanding results and incredible support, allowing us to retain our samples in-house and stay abreast of changing guidelines. The addition of these new applications will help us gain a better understanding of what drives cancers down to a molecular level,” said Thomas Stricker, MD, PhD, Pathology Lab Director, Center for Molecular and Genomic Studies, Tennessee Oncology.
The laboratory at Tennessee Oncology will streamline multiple NGS tests within one end-to-end workflow, allowing for a faster turnaround time and consolidating testing to save sample material. By combining RNA sequencing, CGP, and liquid biopsy testing,SOPHiA DDM™ delivers a comprehensive molecular view of cancer, improving a broader understanding of cancer biology for research that can help to improve future clinical decision-making and treatment planning for complex cancer cases.
“We are excited to expand our support of Tennessee Oncology and its network of oncology practices that are driving the future of community-based cancer care, especially as they bring these sophisticated tests to often underserved communities," said John Carey, Managing Director, NORAM, SOPHiA GENETICS. "By furthering their research and providing access to advanced cancer testing, Tennessee Oncology is innovating the cancer landscape and improving outcomes for patients in need.”
For more information on how labs can benefit from SOPHiA’s end-to-end workflows across a multitude of applications, visit SOPHiAGENETICS.com, or connect on LinkedIn. For more information on Tennessee Oncology, visit tnoncology.com, or connect on LinkedIn.
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to deliver world-class care to patients with cancer and rare disorders across the globe. It is the creator of SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.
About Tennessee Oncology:
Tennessee Oncology, one of the nation’s largest community-based cancer care practices, is home to one of the leading clinical trial networks in the country. Established 1976 in Nashville, Tennessee Oncology’s mission remains unchanged: To provide access to high-quality cancer care and the expertise of clinical research for all patients, at convenient locations within their community and close to their home. Our growing network of physicians and locations is based on this mission. For more information, visit www.tnoncology.com.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.
Forward-Looking Statements
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding SOPHiA GENETICS future results of operations and financial position, business strategy, products and technology, partnerships and collaborations, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on SOPHiA GENETICS’ management’s beliefs and assumptions and on information currently available to the company’s management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in the company’s filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of its date. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in the company’s expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Media Contact:
Kelly Katapodis
SOPHiA GENETICS is excited to attend this year’s Association of Molecular Pathology (AMP) Annual Meeting!
Find us at booth #1131 to learn about how we are enabling breakthrough innovations in cancer research.
From our collaboration with Memorial Sloan Kettering cancer Center to decentralize MSK-ACCESS and MSK-IMPACT, to your launch of SOPHiA DDM™ Residual Acute Myeloid (RAM) Solution, we are committed to supporting clinical researchers with variant detection and analysis, biomarker discovery, and therapy selection.
Check out the full program:
Nov 20 | Corporate Workshops | 214 Level 2
11:00 – 11:50 am
Insights with Impact: Empowering Laboratories with a Decentralized MSK Solution for CGP
Presenters:
12:00 – 12:50 pm
Strategic Collaborations for Expanding Liquid Biopsy Use Globally
Presenters:
Nov 23 | Poster Session
9:15 – 10:15 am
Analytical Validation of the Decentralized MSK-ACCESS® powered with SOPHiA DDM™ Solution
Authored by:
Florian Klemm 1*, Fuad Mohammad 1, Fabio De Martino 1, Yvan Wenger 1, Jacklyn Casanova-Murphy 2, Anita Bowman 2, Brian Loomis 2,3, A. Rose Brannon 2, Michael F. Berger 2,3, Zhenyu Xu 1
1 SOPHiA GENETICS SA, Data Science Department, Rolle, Switzerland
2 Memorial Sloan Kettering Cancer Center, Department of Pathology and Laboratory Medicine, New York, NY
3 Memorial Sloan Kettering Cancer Center, Center for Molecular Oncology, New York, NY
SOPHiA GENETICS is excited to attend this year’s American Society of Human Genetics (ASHG) Annual Meeting in Denver, Colorado.
Stop by booth #765 for a chance to experience the new-generation SOPHiA DDM™ Platform and hear about the latest Alamut™ Visual Plus and WGS news. Come and network with our team of experts, partners, and users to discuss how our solutions are helping navigate the complex mutational landscape of rare and inherited diseases and pharmacogenomics.
Check out the full program:
Tuesday, Nov 6 | 2:30 – 4:30 pm | Hall F
Poster
Authored by:
Jian Yu, Ivan Protopopov, Dmitri Ivanov, Ximena Bonilla Bustillo, Marie Pireyre, Tamara Maas, Zhenyu Xu
Add To CalendarWednesday, Nov 7 | 12:00 – 12:30 pm
Co-lab Talk
Presented by:
Boston, MA and Rolle, Switzerland, July 24, 2024 – SOPHiA GENETICS (Nasdaq: SOPH), a cloud-native healthcare technology company and a leader in data-driven medicine, announced today that OncoHelix, an internationally recognized research and diagnostics laboratory for precision diagnostics, will implement MSK-ACCESS® powered with SOPHiA DDM™. The organization, which currently uses the SOPHiA DDM™ Platform for myeloid testing, will use the new liquid biopsy solution to advance its oncology testing capabilities. OncoHelix will be live on MSK-ACCESS® powered with SOPHiA DDM™ later this summer.
OncoHelix is based in Calgary, Canada, and offers specialized genomic and molecular testing services globally. OncoHelix works in partnership with the Hematology Translational Lab (HTL) at the University of Calgary and has helped significantly advance the University’s precision oncology and immunology research pipelines.
“Our mission at OncoHelix is to offer exceptional clinical-grade molecular and immune profile testing. That mission is predicated on using the most cutting-edge technology to allow for the rapid validation of genomic panels, sequencing, and analysis,” said Dr. Pinaki Bose, Co-founder and Executive Vice President, OncoHelix. “The SOPHiA DDM™ Platform has supported our mission over the last year, and we look forward to implementing MSK-ACCESS® powered with SOPHiA DDM™ to advance our liquid biopsy offering.”
Liquid biopsy testing provides an alternative testing method to traditional solid tumor biopsy, which can be especially helpful when patients are facing limitations such as insufficient material or poor tissue quality, or simply need a less invasive method of biopsy. Liquid biopsy testing extracts cell-free DNA (cfDNA) from blood plasma, revealing circulating tumor DNA (ctDNA). This approach, obtained through a simple blood draw, expedites clinical decisions, accelerates results for researchers and clinicians, and streamlines monitoring.
“OncoHelix has quickly become a trusted leader in precision oncology testing and that is due, in part, to its unrelenting focus on offering the most advanced technology solutions on the market,” said John Carey, Managing Director, NORAM, SOPHiA GENETICS. “We are excited to expand our relationship with OncoHelix by offering this new liquid biopsy solution and continue supporting the company’s commitment to tackling cancer research head-on via targeted testing.”
“This milestone builds on our long-term and successful collaboration in genomic profiling for solid tumours and hemoatological malignancies. MSK-ACCESS® powered with SOPHiA DDM™ marks a major advancement in cancer genomic profiling using circulating free DNA and enhances our ability to gain insights from cancers when tissue biopsy is unavailable,” notes Dr. Faisal Khan, Co-founder and CEO at OncoHelix.
MSK-ACCESS® powered with SOPHiA DDM™ is a decentralized version of a highly validated ctDNA assay developed by Memorial Sloan Kettering Cancer Center (MSK) that involves the deep sequencing of 146 key cancer-associated genes. The offering combines the sophisticated analytics, state-of-the-art algorithms, and global network of the SOPHiA DDM™ Platform, with the scientific and clinical expertise of MSK in cancer genomics to provide a best-in-class liquid biopsy solution.
For more information, visit SOPHiAGENETICS.com, or connect on LinkedIn. For more information on OncoHelix, visit oncohelix.org, or connect on LinkedIn.
# # #
About SOPHiA GENETICS
SOPHiA GENETICS (Nasdaq: SOPH) is a cloud-native healthcare technology company on a mission to expand access to data-driven medicine by using AI to unlock insights to deliver world-class care to patients across the globe. It is the creator of SOPHiA DDM™, a platform that analyzes complex genomic and multimodal data and generates real-time, actionable insights for a broad global network of hospital, laboratory, and biopharma institutions. For more information, visit SOPHiAGENETICS.COM and connect with us on LinkedIn.
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures, unless specified otherwise. The information in this press release is about products that may or may not be available in different countries and, if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact [email protected] to obtain the appropriate product information for your country of residence.
Memorial Sloan Kettering (MSK) has institutional financial interests related to SOPHiA GENETICS.
SOPHiA GENETICS Forward-Looking Statements:
This press release contains statements that constitute forward-looking statements. All statements other than statements of historical facts contained in this press release, including statements regarding our future results of operations and financial position, business strategy, products, and technology, as well as plans and objectives of management for future operations, are forward-looking statements. Forward-looking statements are based on our management’s beliefs and assumptions and on information currently available to our management. Such statements are subject to risks and uncertainties, and actual results may differ materially from those expressed or implied in the forward-looking statements due to various factors, including those described in our filings with the U.S. Securities and Exchange Commission. No assurance can be given that such future results will be achieved. Such forward-looking statements contained in this press release speak only as of the date hereof. We expressly disclaim any obligation or undertaking to update these forward-looking statements contained in this press release to reflect any change in our expectations or any change in events, conditions, or circumstances on which such statements are based, unless required to do so by applicable law. No representations or warranties (expressed or implied) are made about the accuracy of any such forward-looking statements.
Media Contact:
Kelly Katapodis
SOPHiA GENETICS products are for Research Use Only and not for use in diagnostic procedures unless specified otherwise.
SOPHiA DDM™ Dx Hereditary Cancer Solution, SOPHiA DDM™ Dx RNAtarget Oncology Solution and SOPHiA DDM™ Dx Homologous Recombination Deficiency Solution are available as CE-IVD products for In Vitro Diagnostic Use in the European Economic Area (EEA), the United Kingdom and Switzerland. SOPHiA DDM™ Dx Myeloid Solution and SOPHiA DDM™ Dx Solid Tumor Solution are available as CE-IVD products for In Vitro Diagnostic Use in the EEA, the United Kingdom, Switzerland, and Israel. Information about products that may or may not be available in different countries and if applicable, may or may not have received approval or market clearance by a governmental regulatory body for different indications for use. Please contact us to obtain the appropriate product information for your country of residence.
All third-party trademarks listed by SOPHiA GENETICS remain the property of their respective owners. Unless specifically identified as such, SOPHiA GENETICS’ use of third-party trademarks does not indicate any relationship, sponsorship, or endorsement between SOPHiA GENETICS and the owners of these trademarks. Any references by SOPHiA GENETICS to third-party trademarks is to identify the corresponding third-party goods and/or services and shall be considered nominative fair use under the trademark law.